サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1320222

遺伝子組換えエリスロポエチン市場：タイプ別、適応症別、最終用途別、国別、地域別-2023-2030年の産業分析、市場規模、市場シェア、予測

Recombinant Erythropoietin Market with COVID-19 Impact Analysis, By Type, By Indication, By End-Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日
ページ情報
英文 250 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
遺伝子組換えエリスロポエチン市場：タイプ別、適応症別、最終用途別、国別、地域別-2023-2030年の産業分析、市場規模、市場シェア、予測
出版日: 2023年07月01日
発行: AnalystView Market Insights
ページ情報: 英文 250 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

遺伝子組換えエリスロポエチンの市場規模は2022年に68億5,128万米ドルとなり、2023年から2030年にかけてCAGR 2.1%で拡大

遺伝子組換えエリスロポエチン市場-市場力学：

慢性腎臓病（CKD）の頻度上昇と効率的な貧血治療の必要性が市場需要を促進

慢性腎臓病（CKD）の頻度上昇と効率的な貧血治療の必要性が遺伝子組換えエリスロポエチン（rEPO）の需要を促進しています。エポエチン・アルファとしても知られるrEPOは、赤血球形成を増加させ、貧血症状を緩和し、輸血の必要性を最小限に抑えるために使用されます。高齢化やライフスタイルの変化などによりCKDの有病率が世界的に上昇する中、CKD患者の貧血治療に不可欠な治療オプションとしてrEPOに対するヘルスケア部門のニーズは高まっています。

遺伝子組換えエリスロポエチン市場-主な洞察：

  • 弊社のリサーチアナリストが分析したところによると、世界の遺伝子組換えエリスロポエチン市場は予測期間（2023-2030年）にCAGR約2.1%で毎年成長すると予測されています。
  • 組換え型エリスロポエチン産業は、慢性腎臓病（CKD）の頻度上昇と効率的な貧血治療の必要性により、著しい速度で成長すると予測される
  • タイプ別セグメンテーションでは、エポエチンアルファが2022年に最大の市場シェアを示すと予測されました。
  • 適応症別では、がん関連貧血が2022年の主要タイプでした。
  • 地域別では、アジア太平洋地域が2022年の売上高でトップ

遺伝子組換えエリスロポエチン市場-セグメンテーション分析：

遺伝子組換えエリスロポエチンの世界市場は、タイプ、適応症、最終用途、地域に基づいてセグメント化されます。

市場はタイプによって2つのカテゴリーに分けられる：エポエチンアルファ、ダルベポエチンアルファです。エポエチン・アルファは遺伝子組換えエリスロポエチン（rEPO）の一種で、慢性腎臓病、がん化学療法、その他の疾患による貧血の治療に頻繁に使用されるため、高い需要があります。エポエチンアルファは赤血球の合成を促進し、貧血症状の軽減や患者のQOL向上に役立ちます。

市場は適応症別に4つのカテゴリーに分類される：慢性腎疾患に伴う貧血（CKD）、がん関連貧血、HIV関連貧血、その他です。がん関連貧血分野は市場を独占しており、予測期間中もその優位性を維持するとみられます。がん関連貧血の治療では、遺伝子組換えエリスロポエチン（rEPO）の需要が大きいです。rEPO、特にEpoetin Alfaは赤血球合成を増加させるために使用され、輸血の必要性を低下させ、がん患者の一般的な健康状態を向上させる。

遺伝子組換えエリスロポエチン市場-地理的洞察：

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。アジア太平洋地域で遺伝子組換えエリスロポエチン（rEPO）の需要が高いのにはいくつかの理由があります。この地域では、慢性腎臓病やがんなどの貧血関連疾患に苦しむ患者が多いです。さらに、この地域では人口の高齢化が急速に進んでおり、慢性疾患の頻度が高まっていることから、貧血管理の治療オプションとしてrEPOの需要が高まっています。さらに、ヘルスケアインフラの改善や医療技術の向上が、アジア太平洋市場におけるrEPOの使用量増加につながっています。その結果、製薬会社はrEPOやその他の生物製剤の需要増に対応するため、この地域での存在感を高めています。

遺伝子組換えエリスロポエチン市場-競合情勢：

遺伝子組換えエリスロポエチン（rEPO）は貧血関連疾患の治療において重要な働きをするため、厳しい競合に直面しています。複数の製薬会社がrEPOの開発と販売に携わっており、競合環境が形成されています。市場は、確立されたブランドと充実した販売網を持つ主要企業によって支配されています。各社は、製品の有効性、安全性、費用対効果を重視することで、競争上の優位性を確保しようとしています。さらに、継続的な研究開発活動により、製剤や投与方法の改善を図り、患者の快適性とコンプライアンスを高めています。競合勢力はさらに、厳格な規制遵守と特許保護の影響を受けています。

最近の動き

2023年2月、食品医薬品局はJesduvroq錠（daprodustat）を、少なくとも4ヵ月間透析を受けている慢性腎疾患に起因する貧血（赤血球数低下）に対する初の経口薬として承認しました。Jesduvroqは透析患者以外には認可されていないです。FDAが承認している他の治療法は、血流への注射または皮膚からの投与です。

調査の主な特徴

  • 遺伝子組換えエリスロポエチン市場に関するこの調査レポートは、2022年を基準年として、市場規模、複合年間成長率（CAGR %）、推定・予測（2023-2030年）を提供します。
  • この調査レポートは、遺伝子組換えエリスロポエチン市場に関する最新動向の洞察を顧客に提供します。
  • この調査レポートは、さまざまなセグメント/国における潜在的な成長機会を解明し、遺伝子組換えエリスロポエチン市場の魅力的な投資提案マトリクスを解説しています。
  • 遺伝子組換えエリスロポエチン市場における新たな投資機会、既存企業が直面する課題、持続的な成長要因を特定
  • 遺伝子組換えエリスロポエチン市場規模、予測、CAGR、市場力学に対するCOVID-19の影響について調査範囲で詳細に論じています。COVID後の遺伝子組換えエリスロポエチン市場に関する詳細な洞察もカバーします。
  • 本レポートのユーザーに遺伝子組換えエリスロポエチン市場の包括的な見解を提供するために、遺伝子組換えエリスロポエチン市場の競合情勢と主要イノベーター分析も含めています。
  • 本調査では、市場規模、成長率、魅力度に基づき、すべての業界セグメントをベンチマークとした成長展望マッピング分析を網羅しています。
  • 主要市場参入企業の詳細な企業プロファイルを掲載しており、組み換えエリスロポエチン市場で活動する企業の財務情報や戦略的イニシアチブを理解するのに役立ちます。
  • さらに、本レポートでは、世界レベルだけでなく地域レベルで市場に関与する主要参入企業の重要な買収＆合併、提携＆ジョイントベンチャー、新発売、研究開発、地域展開も明らかにしています。
  • 遺伝子組換えエリスロポエチンの世界市場レポートは、主にサプライヤー、投資家、新規参入者、流通業者、金融アナリストなど、この業界の様々な利害関係者に対応しています。

目次

第1章 遺伝子組換えエリスロポエチン市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 遺伝子組換えエリスロポエチンの主要な市場動向

  • 遺伝子組換えエリスロポエチンの市場促進要因
  • 遺伝子組換えエリスロポエチン市場抑制要因
  • 遺伝子組換えエリスロポエチンの市場機会
  • 遺伝子組換えエリスロポエチン市場の将来動向

第4章 遺伝子組換えエリスロポエチン産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 遺伝子組換えエリスロポエチン市場：COVID-19感染症の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 遺伝子組換えエリスロポエチンの市場情勢

  • 遺伝子組換えエリスロポエチン市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 確立された企業の分析
    • 新興企業の分析

第7章 遺伝子組換えエリスロポエチン市場- タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • エポエチンアルファ
    • ダルベポエティンアルファ

第8章 遺伝子組換えエリスロポエチン市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 慢性腎臓病（CKD）に伴う貧血
    • がん関連の貧血
    • HIV関連貧血
    • その他

第9章 遺伝子組換えエリスロポエチン市場- 最終用途別

  • 概要
    • 最終用途別のセグメントシェア分析
    • 病院と診療所
    • 透析センター
    • 腫瘍センター
    • その他

第10章 遺伝子組換えエリスロポエチン市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の遺伝子組換えエリスロポエチンの主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の遺伝子組換えエリスロポエチンの主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の遺伝子組換えエリスロポエチンの主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの遺伝子組換えエリスロポエチンの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの遺伝子組換えエリスロポエチンの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 遺伝子組換えエリスロポエチン産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Amgen Inc.
    • Johnson &Johnson
    • LG Chem Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Celltrion Inc.
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • Biocon Limited
    • Sandoz International GmbH
    • Intas Pharmaceuticals Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • 3SBio Inc.
    • CJ CheilJedang Corporation
    • BioSidus SA

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Recombinant Erythropoietin Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Recombinant Erythropoietin Market, by Type 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Recombinant Erythropoietin Market, by Indication 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: End-Use Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End-Use
  • TABLE Global Recombinant Erythropoietin Market, by End-Use 2018-2030 (USD Million)
  • TABLE Recombinant Erythropoietin Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Recombinant Erythropoietin Market, by Region 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE North America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Recombinant Erythropoietin Market, by End-Use, 2018-2030 (USD Million)
目次
Product Code: ANV1533

REPORT HIGHLIGHT

Recombinant Erythropoietin Market size was valued at USD 6,851.28 Million in 2022, expanding at a CAGR of 2.1% from 2023 to 2030.

Recombinant erythropoietin (rEPO) is a genetically modified type of erythropoietin, a hormone generated normally in the kidneys that controls red blood cell synthesis. rEPO is created through biotechnology, often using mammalian cells. It possesses the same form and function as endogenous erythropoietin and is utilized for treating anemia-related illnesses including chronic kidney failure, cancer-related anemia, and anemia caused by certain medicinal therapies. rEPO increases oxygen-carrying capacity in the blood by promoting the synthesis of red blood cells, enhancing energy levels, and minimizing the requirement for blood transfusions in patients with anemia.

Recombinant Erythropoietin Market- Market Dynamics:

Rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy to propel market demand

The rising frequency of chronic kidney disease (CKD) and the necessity for efficient anemia therapy is driving demand for recombinant erythropoietin (rEPO). Anaemia is common in CKD patients due to decreased erythropoietin production. rEPO, also known as Epoetin Alfa, is used to increase red blood cell formation, easing anemia symptoms and minimizing the requirement for blood transfusions. As the worldwide prevalence of CKD climbs owing to reasons such as aging populations and lifestyle changes, the healthcare sector's need for rEPO as a vital therapeutic option for anemia treatment in CKD patients grows.

Recombinant Erythropoietin Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Recombinant Erythropoietin market is estimated to grow annually at a CAGR of around 2.1% over the forecast period (2023-2030)
  • The Recombinant Erythropoietin industry is projected to grow at a significant rate due to the rising frequency of chronic kidney disease (CKD) and the necessity for efficient anaemia therapy
  • Based on Type segmentation, Epoetin Alfa was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Cancer Related Anemia was the leading type in 2022
  • On the basis of region, Asia Pacific was the leading revenue generator in 2022

Recombinant Erythropoietin Market- Segmentation Analysis:

The Global Recombinant Erythropoietin Market is segmented on the basis of Type, Indication, End-Use, and Region.

The market is divided into two categories based on Type: Epoetin Alfa, Darbepoetin Alfa. Epoetin Alfa, a kind of recombinant erythropoietin (rEPO), is in high demand since it is frequently used to treat anemia caused by chronic kidney disease, cancer chemotherapy, and other medical diseases. Epoetin Alfa promotes red blood cell synthesis, which helps to reduce anemia symptoms and enhance patients' quality of life.

The market is divided into four categories based on Indication: Anemia Associated with Chronic Kidney Disease (CKD), Cancer Related Anemia, HIV-Associated Anemia, Others. The Cancer Related Anemia sector dominates the market and is likely to maintain its dominance during the forecast period. In the treatment of cancer-related anemia, recombinant erythropoietin (rEPO) is in great demand. Patients taking chemotherapy for cancer often have a reduction in red blood cell formation, resulting in anemia. rEPO, especially Epoetin Alfa, is used to increase red blood cell synthesis, lowering the need for blood transfusions and increasing the general well-being of cancer patients.

Recombinant Erythropoietin Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. Several reasons contribute to the high demand for recombinant erythropoietin (rEPO) in the Asia Pacific area. A considerable patient population in the area suffers from anemia-related illnesses such as chronic renal disease and cancer. Furthermore, the region's rapidly aging population and rising frequency of chronic illnesses boost demand for rEPO as a treatment option for anemia management. Furthermore, improving healthcare infrastructure as well as medical technology improvements led to the increased usage of rEPO in the Asia Pacific market. As a consequence, pharmaceutical firms are increasing their presence in the area to address the increasing demand for rEPO and other biologics.

Recombinant Erythropoietin Market- Competitive Landscape:

Because of its critical function in treating anemia-related disorders, recombinant erythropoietin (rEPO) faces severe competition. Several pharmaceutical firms are involved in the development and marketing of rEPO, creating a competitive environment. The market is dominated by key firms with well-established brands and substantial distribution networks. Companies strive for a competitive advantage by emphasizing product efficacy, safety, and cost-effectiveness. Furthermore, continuous R&D activities seek to enhance formulations and administration modalities, boosting patient comfort and compliance. The competitive dynamics are further influenced by strict regulatory compliance and patent protection.

Recent Developments:

In February 2023, The Food and Drug Administration authorised Jesduvroq tablets (daprodustat) as the first oral medication for anaemia (low red blood cell count) caused by chronic renal disease in individuals who have been receiving on dialysis for at least a four-month period. Jesduvroq is not authorised for non-dialysis patients. Other FDA-approved therapies for this illness are administered through injection into the bloodstream or via the skin.

Key features of the study:

  • This proposed research study on Recombinant Erythropoietin market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Recombinant Erythropoietin market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Recombinant Erythropoietin market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Recombinant Erythropoietin market
  • Impact of COVID-19 on Recombinant Erythropoietin market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Recombinant Erythropoietin market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Recombinant Erythropoietin market, we have also included competitive landscape and key innovator analysis for the Recombinant Erythropoietin market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Recombinant Erythropoietin market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Recombinant Erythropoietin market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET KEY PLAYERS

  • Amgen Inc.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Celltrion Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Novartis AG
  • Biocon Limited
  • Sandoz International GmbH
  • Intas Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • 3SBio Inc.
  • CJ CheilJedang Corporation
  • BioSidus SA

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY TYPE

  • Epoetin Alfa
  • Darbepoetin Alfa

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY INDICATION

  • Anemia Associated with Chronic Kidney Disease (CKD)
  • Cancer Related Anemia
  • HIV-Associated Anemia
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY END-USE

  • Hospitals and Clinics
  • Dialysis Centers
  • Oncology Centers
  • Others

GLOBAL RECOMBINANT ERYTHROPOIETIN MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Recombinant Erythropoietin Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Recombinant Erythropoietin Market Snippet by Type
    • 2.1.2. Recombinant Erythropoietin Market Snippet by Indication
    • 2.1.3. Recombinant Erythropoietin Market Snippet by End-Use
    • 2.1.4. Recombinant Erythropoietin Market Snippet by Country
    • 2.1.5. Recombinant Erythropoietin Market Snippet by Region
  • 2.2. Competitive Insights

3. Recombinant Erythropoietin Key Market Trends

  • 3.1. Recombinant Erythropoietin Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Recombinant Erythropoietin Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Recombinant Erythropoietin Market Opportunities
  • 3.4. Recombinant Erythropoietin Market Future Trends

4. Recombinant Erythropoietin Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Recombinant Erythropoietin Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Recombinant Erythropoietin Market Landscape

  • 6.1. Recombinant Erythropoietin Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Recombinant Erythropoietin Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Epoetin Alfa
    • 7.1.3. Darbepoetin Alfa

8. Recombinant Erythropoietin Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Anemia Associated with Chronic Kidney Disease (CKD)
    • 8.1.3. CancerRelated Anemia
    • 8.1.4. HIV-Associated Anemia
    • 8.1.5. Others

9. Recombinant Erythropoietin Market - By End-Use

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-Use, 2022 & 2030 (%)
    • 9.1.2. Hospitals and Clinics
    • 9.1.3. Dialysis Centers
    • 9.1.4. Oncology Centers
    • 9.1.5. Others

10. Recombinant Erythropoietin Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Recombinant Erythropoietin Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Recombinant Erythropoietin Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Recombinant Erythropoietin Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Recombinant Erythropoietin Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Recombinant Erythropoietin Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-Use, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Recombinant Erythropoietin Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Amgen Inc.
    • 11.2.2. Johnson & Johnson
    • 11.2.3. LG Chem Ltd.
    • 11.2.4. Dr. Reddy's Laboratories Ltd.
    • 11.2.5. Celltrion Inc.
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Roche Holding AG
    • 11.2.8. Novartis AG
    • 11.2.9. Biocon Limited
    • 11.2.10. Sandoz International GmbH
    • 11.2.11. Intas Pharmaceuticals Ltd.
    • 11.2.12. Teva Pharmaceutical Industries Ltd.
    • 11.2.13. 3SBio Inc.
    • 11.2.14. CJ CheilJedang Corporation
    • 11.2.15. BioSidus SA

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us